High soluble CD30 levels and associated anti-HLA antibodies in patients with failed renal allografts

Abstract

Introduction: Serum soluble CD30 (sCD30), a 120-kD glycoprotein that belongs to the tumor necrosis factor receptor family, has been suggested as a marker of rejection in kidney transplant patients. The aim of this study was to evaluate the relationship between sCD30 levels and anti-HLA antibodies, and to compare sCD30 levels in patients undergoing hemodialysis (HD) with and without failed renal allografts and transplant recipients with functioning grafts. Methods: 100 patients undergoing HD with failed grafts (group 1), 100 patients undergoing HD who had never undergone transplantation (group 2), and 100 kidney transplant recipients (group 3) were included in this study. Associations of serum sCD30 levels and anti-HLA antibody status were analyzed in these groups. Results: The sCD30 levels of group 1 and group 2 (154 +/- 71 U/mL and 103 +/- 55 U/mL, respectively) were significantly higher than those of the transplant recipients (group 3) (39 +/- 21 U/mL) (p<0.001 and p<0.001). The serum sCD30 levels in group 1 (154 +/- 71 U/mL) were also significantly higher than group 2 (103 +/- 55 U/mL) (p<0.001). Anti-HLA antibodies were detected in 81 (81%) and 5 (5%) of patients in groups 1 and 2, respectively (p<0.001). When multiple regression analysis was performed to predict sCD30 levels, the independent variables in group 1 were the presence of class I anti-HLA antibodies (beta = 0.295; p = 0.003) and age (beta = -0.272; p = 0.005), and serum creatinine (beta = 0.218; p = 0.027) and presence of class II anti-HLA antibodies (standardized beta = 0.194; p = 0.046) in group 3. Conclusions: Higher sCD30 levels and anti-HLA antibodies in patients undergoing HD with failed renal allografts may be related to higher inflammatory status in these patients.